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Antonello Mai1,5*Abstract
Epigenetic pathways play a pivotal role in the development and function of the immune system. Over the last
decade, a growing body of studies has been published out seeking to explain a correlation between epigenetic
modifications and the development of autoimmune disorders. Epigenetic changes, such as DNA methylation,
histone modifications, and noncoding RNAs, are involved in the pathogenesis of autoimmune diseases mainly by
regulating gene expression. This paper reviews the importance of epigenetic alterations during the development of
the most prevalent human autoimmune diseases, such as systemic lupus erythematosus (SLE), rheumatoid arthritis
(RA), systemic sclerosis (SSc), Sjogren’s syndrome (SS), autoimmune thyroid diseases (AITD), and type 1 diabetes
(T1D), aiming to provide new insights in the pathogenesis of autoimmune diseases and the possibility to develop
novel therapeutic approaches targeting the epigenome.
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Epigenetic mechanisms, known for their ability to
regulate gene transcription and genomic stability, are
key players for maintaining normal cell growth, develop-
ment, and differentiation [1]. The term “epigenetics” can
be outlined as the meiotically/mitotically heritable
alterations in gene expression, related to environmental
factors, without changes to the sequence of bases in the
DNA [1]. Since genome-wide profiling in some cases
does not give a sufficient answer to explain the complex
biological processes in autoimmune disorders, epigenetic
modifications are retained additional regulators in
immune responses (Fig. 1). Epigenetic dysregulation
directly influences the development of autoimmunity by
regulating immune cell functions [2]. The recognition of
the complexity of the interaction between epigenetic
events and the alteration of the immune system in
autoimmune disorders is a prominent challenge for the
discovery of novel potential therapeutic strategies.
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identified as crucial regulators in cellular immunity,
owing to their mechanisms in modulating gene expres-
sion and transcription in targeted cells and tissues [3].
Extensive evidences indicate that autoimmune diseases
are mainly an interplay of genetic and non-genetic
factors, although the role of the latter ones often
remains unclear. Over the last decade, the influence of
epigenetic modifications on innate and adaptive immunity
has been intensively investigated, especially in auto-
immune disorders.Epigenetic mechanisms
DNA methylation
DNA methylation is one of the most studied epigenetic
marks and typically occurs at the pyrimidine C5 position
of cytosine residues by transferring a methyl group from
S-adenosyl-L-methionine (SAM) through the catalytic
action of DNA methyltransferases (DNMTs) [4–6]. DNA
methylation influences a large variety of biological
processes such as transcriptional repression, reversible
promoter silencing, and chromosomal instability [7, 8].
The various functions and diverse subtypes of DNMTs
have been summarized well in various reviews [9–11].le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Fig. 1 Schematic representation of key epigenetic mechanisms (DNA methylation, histone post-translational modifications, and RNA-based
mechanism) involved in the pathogenesis of autoimmune diseases, including SLE, RA, SSc, SS, AITD, and T1D
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the maintenance of the T cell regulation. Recent findings
underlined the critical role of DNA methylation in
numerous autoimmune diseases by altering gene expres-
sion profiles [12–15]. Several factors such as environ-
mental influences, genetic variants, drugs, and miRNAs
influencing the DNA methylation status have been
linked to autoimmune disorders.
Histone modifications
Histone-modifying enzymes have an essential role in
modulating chromatin compaction state, nucleosomal
processes, and DNA repair [16–18]. Some HDAC inhibi-
tors (HDACi) have been widely studied as a means to in-
crease the transcription of various genes, including those
involved in autoimmunity [19–21]. Moreover, HDACi
have been described to influence immune and inflamma-
tory processes, mainly involving T cells [22, 23]. Acetyl
and methyl marks inserted on histones could also
interact with the corresponding “reader” proteins to addcomplexity to this scenario. Some evidence suggested
that posttranslational modifications are implicated in the
development and regulation of different cell lines and in
the modulation of immune tolerance and autoimmune
disorders [24, 25].
Noncoding RNAs
Long noncoding RNAs (lncRNAs) are a huge and di-
verse class of transcribed RNA molecules with a length
of more than 200 nucleotides. Usually, they are capped,
polyadenylated, and spliced without having any coding
function for proteins [26]. LncRNAs have been described
as key players of gene regulation in various human
pathologies due to their implication in numerous cellular
and biological events regulating heterochromatin forma-
tion, histone modifications, DNA methylation targeting,
and gene silencing [27, 28]. Furthermore, lncRNA can
activate regulatory complexes regulating the develop-
ment and differentiation of various immune cell types
via an active protein expression control. MiRNAs are
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mRNAs and are implicated in numerous disorders, such
as cancers, inflammatory processes, and metabolic
diseases [29, 30]. Due to their essential role in the
hematopoietic development, as well as cell activation
and differentiation, abnormal expression of miRNAs
might lead to the onset of autoimmune diseases [31, 32].
Systemic and organ-specific autoimmune diseases
Autoimmune diseases are characterized by an immune
response to antigenic components of the host itself
(autoantigens). Two main types of autoimmune diseases
can be distinguished: on the one hand, the systemic ones
and on the other, the organ-specific ones. In systemic
diseases, the immune system attacks in a generalized
manner its own antigens in several organs, while in
organ-specific diseases the immune response is directed
towards a single organ. Examples of systemic and
organ-specific autoimmune diseases with known autoan-
tigen targets are illustrated in Table 1.
Systemic autoimmune rheumatic diseases (SARDs)
Systemic autoimmune rheumatic diseases (SARDs)
belong to a group of rare chronic inflammatory condi-
tions including rheumatoid arthritis (RA), systemic lupus
erythematosus (SLE), systemic sclerosis (SSc), and
Sjogren’s syndrome (SS). Autoimmunity is defined by
the breakdown of self-tolerance that produces a state of
abnormal humoral and cell-mediated responses against
self-components. Collectively, SARDs affect up to 5% of
the world population and, in particular, people of
work-force age [33, 34]. Until now, no effective treat-
ments have been identified for SARDs, even though the
use of glucocorticoids has been considered as a first-line
therapy. Nowadays, however, antimalarial and immuno-
suppressive drugs are most commonly used due to their
limited long-term side effects. Such autoimmune disor-
ders are often associated with an autoimmune dysregula-
tion which determines morbidity and, in most cases,
premature mortality [35, 36]. In particular, most of these
conditions happen when the immune system produces
autoantibodies (ANA) directed against intracellular anti-
gens. So, ANA are considered as convincing serological
hallmarks of SARDs, which are routinely detected via an
indirect immunofluorescence (IF) assay [37]. Although
many progresses have been performed in the last 15
years, there is an unmet need to find an innovative and
successful therapy to fight SARDs, especially RA, the
most prevalent autoimmune disease. Understanding the
molecular mechanisms of SARDs appears to be ex-
tremely important to achieve beneficial outcomes in
these chronic conditions. However, similar biologic
pathways that underlie SARDs in RA, SLE, and SSc may
suggest novel mechanistic similarities. Indeed, thesethree chronic diseases have in common demographic
distribution (the most affected individuals are women),
some signs and symptoms (arthritis, lung and vascular
disease), serological elements (ANA and anti-Ro52/
TRIM21 antibodies), immunological components (type I
interferon signature and complex abnormalities in
CD4C T lymphocyte function, in particular Th17 and
Treg cell subsets), and genetic similarities (e.g., MHC
class II alleles, IRF5, STAT4, PTPN22 loci) [38–44].
More and more studies demonstrated that epigenetically
altered immune components, such as CD4+ T cells and
costimulatory molecules, are key drivers of SARDs,
thereby compromising cellular immune system function
and regulation [45–48]. Characterization of epigenetic
modifications that occur across these autoimmune
diseases may yield valuable insights into their pathogen-
esis and treatment. Thus, in an attempt to determine the
most important epigenetic changes in SARDs, re-
searchers investigated the role of epigenetic processes in
regulating autoimmunity. For many years, epigenetic
implications for the most important related forms of
autoimmunity including RA, SLE, SSc, and SS have been
studied in order to find a tight association between
epigenetics and systemic autoimmune, providing novel
regulatory mechanisms for SARDs (Table 2).
Systemic lupus erythematosus (SLE)
SLE is the most studied autoimmune disease correlated
with epigenetic modification. It especially occurs in
women and is mainly caused by dysregulation of T lym-
phocytes, making the disorder complicated and hard to
handle. SLE is a chronic autoimmune dysfunction char-
acterized by the development of autoantibodies against
nuclear antigens affecting any organ system and tissue,
such as kidney and blood vessels. In a recent study, neu-
trophils and granulocytes from patients with SLE have
been described as totally hypomethylated, especially at
the gene locus of the interferons MX1 and IFI44L [49].
Discrepancies in monozygotic twins propone environ-
mental factors as crucial drivers for the development of
SLE. Epigenetic alterations such as DNA methylation
and histone modifications have been found to be able to
regulate gene expression in mature T cells. Numerous
genes such as CD11a (ITGAL), perforin (PRF1), CD70
(TNFSF7), and CD40LG (TNFSF5) in T lymphocytes of
SLE patients were found to be hypomethylated [50].
Early studies in SLE CD4+ T cells demonstrated a con-
version to autoreactivity and an induced lupus-like syn-
drome after treatment with DNMT inhibitors [51–53].
The auto-reactivity has been shown only in cloned and
polyclonal human and murine CD4+ cells, but not in
CD8+ cells, the reason is still undetermined [53, 54]. How-
ever, there is strong evidence that auto-reactivity develop-
ment is concomitant with an increased expression of the
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Table 2 Epigenetic changes in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc) and Sjogren’s
syndrome (SS)
Autoimmune disease DNA methylation Histone modification miRNA
SLE ↓ CD70, ↓ CD11a,
↓ CD40L, ↓ perforin
↓ T cell
↓ IFN signature [50–63]
↑ H3, H4 methylation
↑ H3, H4 acetylation [64–67]
↑ miR-21, ↑ miR-148a [68–71]
RA ↓ T cell
↑ Synoviocytes [79, 80]
↑ H3 acetylation [82–88] ↑ miR-146a, strong link between many
microRNAs and DNA methylation [90–93]
SSc ↓ T cell
↓ Fibroblasts
↑ Wnt pathway genes [96–98, 102, 103]
Fibroblasts:↓ H3, H4 acetylation
[104, 107, 108]
↑ miR-29a, ↑ miR-196a [109–114]
SS ↓ Type-I IFN pathway genes
↓ T cells [115–121]
No large-scale analysis ↑ miR-146a [122]
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levels of CD11a (ITGAL) transcripts. ITGAL is an integrin
responsible for costimulation and cellular adhesion. The
upstream promoter of ITGAL can be found to be
demethylated in SLE patients’ CD4+ cells and depending
on the disease activity, and progression CD11a can be
found more or less overexpressed [55]. The methylation
status of other specific genes has been linked with SLE
pathogenesis and development. CD40L, a type II
transmembrane protein encoded on the X chromosome
by CD40LG and functioning as a costimulatory molecule,
has been found to be overexpressed in human SLE pa-
tients. It still remains elusive why SLE predominantly af-
fects women. CD40LG methylation patterns have been
associated with female susceptibility to this disease [56].
Following treatment with DNMT inhibitors (azacytidine,
procainamide) or ERK pathway inhibitors (hydralazine,
PD98059), demethylated CD40LG led to induced T cell
autoreactivity in vitro [56]. Overexpressed E4BP4 (NFIL3),
an important human transcription factor, led to the down-
regulation of the autoimmune responses in SLE patients
through inhibiting CD40L expression [57]. Another inter-
esting costimulatory molecule is CD70, encoded by
TNFSF7, a ligand of CD27. Disruption of CD70-CD27
interaction via blocking antibody allows attenuating
lectin-stimulated B cells’ IgG production in vitro [58].
Overexpression in a mouse model can be caused both by
traditional demethylating agents and medications associ-
ated with drug-induced lupus, including hydralazine and
procainamide [59]. Overexpression of CD11a and CD70
in CD4+ cells after histone methyltransferase SUV39H1
recruitment resulted in decreased regulatory factor X1
(RFX1) levels are important for the determination of
CD4+ T cell auto-reactivity [60, 61]. Sunahori et al. could
demonstrate that inhibiting the catalytic subunit of
protein phosphatase 2A (PP2Ac) increased MEK/ERK
phosphorylation levels and elevated DNA methylation
levels as well as diminished CD70 gene expression [62].
Perforin (PRF1), a key regulator gene in cytotoxic CD8+
and NK cells, produces a cytolytic protein allowing thedisruption and lysis of target cellular membranes [63].
PRF1 overexpression in both CD4+ and CD8+ cells,
mediated by the gene promoting methylation state,
has been linked to SLE. Overexpression of IL10 in T
cells from SLE patients is modulated by abnormal
STAT3 activation through the histone acetyltransfer-
ase p300 leading to an increase of specific autoanti-
body production and tissue damage [64]. Another
important interleukin, IL13, has been considered to
play a pivotal role in the development of both human
and murine lupus via Th2 cell differentiation [65].
Histone modification pattern in lupus has been less
investigated than DNA methylation. A heavily methyl-
ated HDAC6 promoter resulted in lower HDAC6
mRNA expression in SLE patients if compared to
healthy controls [66]. MRLlpr lupus-prone mouse
splenocytes showed increased methylation as well as
decreased acetylation of histones H3 and H4 com-
pared to control mice; treatment with HDAC inhibi-
tors (HDACi) normalizes aberrant gene expression
thus reducing disease activity. However, when lupus T
cells are treated by HDACi, including trichostatin A
(TSA) and suberoylanilide hydroxamic acid (SAHA),
alterations of acetylation levels of acid nuclear trans-
port proteins, transcription factors, and cytoskeleton
proteins have been reported [67]. Thus, no valid evi-
dence has been found yet to connect the histone
modifications with SLE activity. Several recent studies
investigated the role of lncRNAs in lupus pathogen-
esis. MiR-21, miR-148a, and miR126 are three micro-
RNAs regulated by methylation that are matched with
a decreased expression of DNMTs in CD4+ T cells of
SLE [68]. MiR-148a elicited the expression of CD70
and CD11a, similar to lupus patients [69]. Further,
overexpressed miR-155 has been found in Treg cell of
MRLlpr mice. Its T cell distribution regulating activity
has been proven in miR-155 deficient mice which
display reduced serum levels of IL4 and IL17A, two
specific cytokines secreted by Th2 and Th17 cells,
respectively [70]. Another study describes increased
Mazzone et al. Clinical Epigenetics           (2019) 11:34 Page 6 of 15serum levels of RANTES in SLE patients harboring,
at the same time, lowered MiR-125a expression [71].
Rheumatoid arthritis (RA)
RA is a chronic and debilitating inflammatory sickness
causing destructive arthritis with diffuse damages to
joints. Epigenetic mechanisms involved in RA include
altered methylation stati in T and B cells as well as in
synovial fibroblasts [72–74]. Early methylation studies
revealed that patients’ T cells showed a remarkable
phenotype, similar to SLE, characterized by global hypo-
methylation [75, 76]. In particular, methotrexate (MTX),
used to treat RA, led to the accumulation of protective
Treg cells by inducing FOXP3 expression through the
promoter demethylation. However, other secondary
effects of MTX, which is namely a folate antagonist, on
the RA evolution cannot yet be ruled out. Further
studies have shown that MTX can reverse the hypo-
methylated status in peripheral blood mononuclear cells
(PBMC) [77, 78]. In 2012, Nakano and colleagues re-
ported the first epigenome-wide study comparing RA
and osteoarthritis (OA) FLS cell lines: out of 1859 differ-
ently methylated loci, around 60% were identified as
hypermethylated [79]. Thanks to a second recent
genome-wide study by de La Rica et al., novel target
genes have been discovered as being differently methyl-
ated, including IL6R, CAPN8, and DPP4. Comparing
rheumatoid arthritis synovial fibroblast (RASF) DNA
methylation with miRNA expression and RASF tran-
scriptome data from the Gene Expression Omnibus
(GEO), more than 200 of the 714 genes identified had
an inverse expression. Moreover, several CpG sites have
been detected to be hypermethylated with concomitantly
reduced miRNA expression [80]. Histone modifications
associated with RA have been less studied; although, an
involvement of these epigenetic changes has been
documented in RA pathogenesis. Dysregulated HDAC
activity in RA PBMCs was not affected by conventional
anti-TNF therapies whereas treatment with MI192, a
HDAC2/3-selective inhibitor, reduced IL6 production in
a dose-dependent manner, thus providing a novel thera-
peutic approach for RA [81]. Wendling et al. evaluated
the relationship between Sirt1 activity/expression and
IL-3 levels in PBMCs. High levels of serum IL-3 associ-
ated with decreased Sirt1 expression and increased
apoptosis in patients with RA have been observed [82].
Kawabata et al. reported an increased HDAC1
expression by TNF-α supplementation in RA synovial
fibroblasts [83–85]. HDACi showed anti-inflammatory
properties in FLS attenuating disease in animal models
of RA. An interesting small open-label trial of givinostat
(a HDACi) in a similar disorder, juvenile idiopathic arth-
ritis, outlined improvement in arthritis and a wide safety
profile [86]. In RA synovial tissues, the equilibriumbetween HATs and HDACs activity is heavily disturbed
owing to the soaring of HAT activity resulting in hypera-
cetylation [87]. An increase in IL6 expression by hypera-
cetylation of histone H3 has been found in synovial
fibroblasts [88]. Ahmed et al. demonstrated that larga-
zole, a marine-derived class I-selective HDACi, provokes
the suppression of the TNFα-induced expression of the
intracellular adhesion molecule-1 (ICAM-1) and the vas-
cular adhesion molecule-1 (VCAM-1) in RASF, as well
as in the reduction of the TNFα-induced MMP2 activity.
Additionally, largazole was shown to modulate expres-
sion levels of HDAC1, HDAC5, and HDAC6. Of particu-
lar interest is the role of HDAC6 in largazole-induced
changes of ICAM-1 and VCAM-1 expression levels [89].
Studies trying to explain the effects of microRNAs on
RA pathogenesis are emerging more and more in the
recent literature. The upregulation of miR-146a with
TNF-α and at the same time the downregulation of
miR-363 and miR-498 has been found in CD4+ cells of
RA patients [90]. Despite these pieces of evidence, vari-
ous studies have shown that miR-146a and miR-155
were decreased in Treg cells after T cell stimulation in
RA patients [91]. Additionally, the expression of
miR-126a in RA turned out to be elevated, leading to
hypomethylated promotors of CD11a and CD70 which
in turn led to their overexpression [92]. Further, the in-
creased expression of miR-21 resulted in Treg cell accu-
mulation in synovial fibroblasts of patients suffering
from RA [93].
Systemic sclerosis (SSc)
SSc is a rare and poorly understood autoimmune disease
of the connective tissue leading to excessive collagen de-
position in the skin and other organs often with a lethal
outcome. Aberrant activation of fibroblasts and collagen
secretion in SSc conduces to fibrosis. Like SLE, early
studies have shown a link to T cell dysfunction and, in
particular, autoreactive T cell transfer signals to sur-
rounding fibroblasts inducing the deposit of collagen
and initiation of fibrosis [94]. The hypomethylation of
CD4+ cells, caused at least in part by the downregulation
of DNMTs, determined the overexpression of several
genes involved in disease progression [95]. Notably, the
downregulation of functional demethylating enzymes
such as DNMT1, MBD3, and MBD4 resulted in lower
levels of methylation at the promoter sites of sensitive
genes implicated in SS leading to the overexpression of
CD40L, CD11a, and CD70 as a relevant feature of SSc
[96–98]. The overexpression of the adaptive immune
costimulatory molecule CD40L, which is crucial for the
integrative role in fibrosis of SSc, is a clear sign of the
disease in plasma and skin fibroblasts [99, 100]. Further-
more, abrogation of CD40/CD40L interaction reduces
fibrosis in a SSc mouse model [101]. Recently, other
Mazzone et al. Clinical Epigenetics           (2019) 11:34 Page 7 of 15pathways related to SSc have been discussed with
particular emphasis on their epigenetic dysregulation
mechanisms. One such pathway, Wnt, increases skin fi-
brosis in SSc patients [102]. Importantly, Dickkopf-1 and
SFRP-1 are both hypermethylated in dermal fibroblasts
and PBMCs in a mouse model of SSc. Thus, treatment
with 5-azacytidine reduces Wnt signaling and deletes
the fibrosis phenotype [103]. Likewise, inactivation of
the collagen suppressor gene FLI1 by epigenetic hyper-
methylation reduces the expression of type I collagen in
fibroblasts from SSc patients [104]. As aforementioned,
fibroblasts play a pivotal role in SSc pathogenesis due to
collagen and extracellular matrix component overpro-
duction. As a consequence, various cytokines may be
produced to dysregulated immune cells further [105].
Reduced H3K27me3 levels were observed as an import-
ant posttranslational modification of CD4+ cells in SSc
leading to the accumulation of the jumonij demethylase
JMJD3 in the aforementioned cells [106]. Similarly, to
SLE, several histone modifications have been noted in
SSc. Both H3 and H4 acetylation is reduced in SSc fibro-
blasts [104]. Indeed, the reduced expression of collagen
in cultured SSc fibroblasts, as well as fibrosis in animal
models, have been reported following HDACi treatment
[107, 108]. MicroRNAs have been implicated in SSc
concerning to dysregulated fibrosis. In details, miR-29a
is decreased in SSc fibroblasts leading to a reduction in
Co1 1 and 3 expressions [109]. MiR-29a can avoid
pulmonary fibrosis and its knock-down increases
pro-fibrotic TGF-β and PDGF-B level. [110]. MiR-21
is regulated by TGF- β and targets smad-7, a key pro-
fibrotic gene [111, 112]. At last, miR-155 mediates fi-
brosis by recruiting keratinocyte growth factor, and
overexpressed miR-196 reduces collagen levels by
regulating collagen 1 [113, 114].
Sjogren’s syndrome (SS)
SS is an autoimmune disease affecting salivary and tear
glands of unknown origin resulting in eye and mouth
dryness. SS is a quite prevalent autoimmune disorder
affecting about four million people in the USA. This
autoimmune illness is associated with autoantibody
production in the blood that is directed against various
tissues of the body leading to an inflammatory response.
Similarly to other autoimmune diseases, reduced DNA
methylation of immune cells is one of the most studied
epigenetic marks in SS. Yin et al. found that the T cell
costimulatory gene CD70 overexpression on CD4+ T
cells is due to the hypomethylation of CD70 promoterin
SS patients [115]. By contrast, lower expression levels of
FOXP3 in SS CD4+ T cells have been correlated with
DNA hypermethylation [116]. A genome-wide DNA
methylation study in naïve CD4+CD45RA+ cells resulted
in the identification of 553 methylated CpG sites. LTA,encoding lymphotoxin α, has been found overexpressed
in both salivary gland tissue and sera of SS patients
[117]. Therefore, its downregulation in the salivary gland
of SS mouse model prevents the development of SS.
Next, a broader comprehensive study of genome-wide
DNA methylation patterns was carried out in whole
blood, peripheral CD19+ B cells, and minor salivary
glands [118]. Differentially hypomethylated sites were
identified in type I IFN-induced genes such as MX1,
IFI44L, PARP9, and IFITM1. The hypomethylation of
their promoter in SS B cells was linked to elevated
mRNA expression levels. Several other genes have been
noted to be differentially methylated, including hypo-
methylated STAT1, IFI44L, IFITM1, and USP8. Con-
versely, the RUNX1 gene, an important transcription
factor involved in T cell development, was hypermethy-
lated among SS patients. Due to reduced expression of
DNMT1 and an increase in GADD45α, epithelial cells
from the salivary gland (SGEC) showed global hypome-
thylation in SS patients. This finding might be associated
with infiltrating B lymphocytes. Increased DNA methyla-
tion levels in SGEC from SS patients have been reported
after the administration of the anti-CD20 monoclonal
antibody rituximab [119]. Konsta et al. showed that re-
duced DNA methylation levels in minor salivary glands
might be correlated with overexpression of the epithelial
protein cytokeratin-19 (gene KRT19) in glandular acini,
while high methylation levels resulted in low levels of
this protein proven by immunohistochemical analyses
[120]. A follow-up study of the same authors proved
their concept as the treatment of a human salivary gland
cell line with the DNMT inhibitor 5-azacytidine led to
KRT19 mRNA and cytokeratin-19 protein overexpres-
sion [121]. To sum up, altered DNA methylation pat-
terns in SGEC may be an important factor in SS
pathophysiology probably at least partially via the
controlling of the KRT19/cytokeratin-19 expression.
Actually, no large-scale studies of histone modifications
as well as of lncRNAs have been carried out in SS.
Increased miR-146a expression has been observed in
PBMCs during the onset of SS [122].
Organ-specific autoimmune diseases
Organ-specific autoimmune diseases, as suggested by
the name, are immune response attacks of the body to-
wards healthy cells of a specific organ system occurring
as a result of either genetic predisposition or environ-
mental influences or a mixture of both. Many efforts
have been performed to understand the inherited
autoimmune responses [123]. A large number of
polymorphic genes are key players in the genesis of these
chronic autoimmune disorders. To date, most details in
these processes still need to be understood better even
though a large number these genes are apparently
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Organ-specific autoimmune diseases are usually related
to specific human leukocyte class II antigens [124]. In
many cases, specific antibodies may be found in patients
with chronic and apparently “idiopathic” organ-specific
autoimmune diseases. Basically, these antibodies bind to
self-antigens in the organ cells or directly on cells, thus
leading to their destruction [125]. Examples are the
autoimmune thyroid diseases (AITD) and type 1 dia-
betes (T1D), in which ANA attack the thyroid gland and
the immune system which compromises the pancreas,
respectively [126, 127]. Normally, the regulation of the
autoimmune process involves antigen-specific regulatory
cells.
Anti-inflammatory cytokines such as IL-10 and TGF-β
are also involved. Up to now, blockers of the immune
response produced a greater success in the clinical use
than treatments exploiting natural immune regulation.
In fact, blocking the immune response is crucial in auto-
immunity, even though immunosuppression leads to
various side effects, including the reactivation of latent
infections and the reduction of immunosurveillance.
Thus, antigen-specific immune therapeutical options, in-
stead of rather unspecific therapies targeting the im-
mune system, are an important goal to reach towards
the treatment of autoimmune disorders. Over the last
decade, scientists figured out that epigenetic changes are
clearly correlated with organ-specific autoimmune
diseases (Table 3). With the aim to better elucidate
mechanisms behind these organ-specific diseases, several
studies have been carried out using approved epi-drugs
[128, 129] (Table 4). Importantly, the discovery of an
epigenetic therapy to treat such autoimmune disorders
may unearth potential biomarkers for disease diagnosis
and prediction.
Autoimmune thyroid diseases (AITDs)
AITDs are a form of autoimmune diseases mediated
by B and T cells. The two main clinical manifesta-
tions of AITDs are Flajani-Basedow-Graves’ disease or
Graves’ disease (GD) and Hashimoto’s thyroiditis
(HT) [130, 131]. HT led to hypothyroidism by
cell-mediated autoimmune destruction, while in GD
specific autoantibodies against the thyroid stimulationTable 3 Main epigenetic modifications in autoimmune thyroid dise
Autoimmune disease DNA methylation Hi
AITD ↑ T cells [133–135] ↓ H
IFN
[24
T1D ↑ T cell
↑ FOXP3 [150, 156, 157]
↑ Hhormone receptor result in hyperthyroidism [132]. Recent
literature shed light on the epigenetic mechanisms in-
volved in the pathogenesis of AITD. DNA methylation,
histone modifications, and lncRNA have been deeply ana-
lyzed in AITDs. However, the clinical utility of epigenetic
modulation still remains elusive. Recent findings con-
firmed that DNA methylation is also in AITDs setting a
very crucial epigenetic mechanism. Global DNA hypome-
thylation was observed in AITD patients, which may
result in overexpressed genes important for a correct im-
mune function, or for the activation of immune cells, ul-
timately leading into an autoimmune attack towards
thyroid tissues [133, 134]. In a genome-wide study, Cai
et al. have detected in GD patients more than 200 hyper-
and hypo-methylated genetic regions, such as ICAM1,
which partly controls cell antigen processing and presen-
tation; DNMT1; and MECP2 genes [133]. Via epigenetic
profiling in CD4+ and CD8+ cells from GD patients,
hypermethylated gene loci of ICAM1, CD247, and CTLA4
associated with T cell receptor signaling were observed.
[133, 134]. Furthermore, hypermethylation of the first in-
tron area in the TSHR gene confirmed that methylation is
involved in the development of AITDs. However, DNA
hypomethylation levels and susceptibility to AITDs have
been correlated to the presence of genetic polymorphisms
of DNA methylation-regulatory genes, such as DNMT1 or
methionine synthase reductase (MTRR) [135]. Histone
modifications play a key role in AITDs, but the exact
mechanism(s) in modulating immune tolerance in AITDs
is still not fully elucidated. Yan et al. described higher
levels of HDAC1 and HDAC2 mRNAs in GD patients
thus histone H4 acetylation levels in peripheral blood
mononuclear cells of GD patients were lower if compared
to those observed in healthy control patient. These results
underline the potential importance of aberrant histone
modifications in GD patients [24]. In patients with GD,
CD4+ and CD8+ cells were presented higher levels of
H3K4me3 and H3K27Ac histone marks [134]. IFN-α, an
important cytokine secreted during viral infections, has
been identified to be able to lead to higher mono and
trimethylation levels of H3K4m in thyroid cells [136].
As previously seen for DNA methylation, genetic
polymorphism of histone-modifying genes may result
in various malfunctions, and/or other further aberrantases (AITDs) and type 1 diabetes (T1D)
stone modification miRNA
3, H4 acetylation
-α enhances H3K4 methylation
, 134, 136, 137]
↓ miR-155-5p,
↓ miR-146a-5p,
↓ miR-125a-3p
↓ miR-197a-3p
Fibroblasts:
↑ miR-21-5p [138–141]
3 acetylation [159] ↑ miR-510
↓ miR-342, ↓ miR-191 [160]
Table 4 Effects of Epi-drugs on autoimmune disorders discussed in this review
Autoimmune
disorder
Epi-drug Chemical structure Target
specificity
Autoimmune pathways involved Ref.
SLE, SSc, SS Azacytidine
(5-AZA)
FDA approved,
2004
DNMTi LFA-1 (CD11a/CD18)
ITGAL, IL-6, Wnt pathway, SFRP-1,
Dickkoft-1, KRT19, cytokeratin-19 protein
[56, 103,
121]
SLE Procainamide DNMT1i CD70, LFA-1, IL-6 [56, 59]
SLE Hydralazine DNMTi CD70 and other costimulatory proteins [56, 59]
SLE, T1D Trichostatin A
(TSA)
Pan HDACi Acid nuclear transport proteins,
cytoskeleton proteins,
IFN-γ production, transcription
activity of Tbx21 in T lymphocytes
[67, 159]
SLE Vorinostat
(SAHA)
FDA approved,
2006
Pan HDACi Acid nuclear transport proteins,
cytoskeleton proteins
[67]
RA Givinostat
(ITF2357)
Pan
HDACi
Arthritic components, T cells [86]
RA Largazole Class I
HDACi
ICAM-1, VCAM-1, MMP2,
TNFα, p38, AKT pathway
[89]
RA Romidepsin
(FK228,
Depsipeptide)
FDA approved,
2009
Class I
HDACi
TNFα, IL-1β, p16LNK4a,
p21 (WAF1/Cip1)
[84]
RA MI192 HDAC2/3
inhibitor
IL6 [81]
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rs3758391 and rs4746720 in the SIRT1 gene were linked
to higher titers of autoantibodies in AITD affected
patients [137]. As previously illustrated for other auto-
immune disorders, microRNAs actively modulate in vari-
ous circumstances the differentiation or activation of
immune cells and immune response. Two of the most
studied miRNA are miR-155-5p and miR-146a-5p, whose
overexpression is believed to break immune tolerance thus
fostering the development of autoimmune diseases. Forexample, GD and HT patients exhibit markedly lower
levels of miR-155-5p and miR-146a-5p in the thyroid
tissues [138]. Although many research’s efforts showed the
potential role of other microRNAs, such as miR-125a-3p,
miR-197a-3p, miR-22-3p, and miR-183-5p, only a small
number of studies investigated their clinical relevance as
diagnostic biomarkers [139–141]. Another epigenetic
process called X chromosome inactivation (XCI) has also
been discussed in correlation with AITDs [142–144]. X
chromosomes are randomly inactivated in females
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chromosomes [145, 146]. Indeed, AITDs are more often
observed in females, confirming the compelling role of
XCI in these autoimmune disorders. Brix et al. demon-
strated that skewed X chromosome inactivation in female
twins with GD and HT was significantly higher than in
the control populations, suggesting a probable role of XCI
in the etiology of AITD [147]. However, Ishido et al.
reported no apparent difference between AITD cases and
controls. By contrast, a notable relationship between
skewed XCI inactivation and the prognosis of GD and HT
was observed [148].
Type 1 diabetes (T1D)
T1D is a chronic autoimmune disease that involves β
cell destruction together with a strong inflammatory re-
sponse. The incidence of diabetes is on the rise world-
wide becoming one of the major causes of death. In
more detail, the body’s own immune system is destroy-
ing the insulin-producing pancreatic β cells first lower-
ing and ultimately ceasing the ability of the pancreas to
produce insulin. To date, the disease cannot be cured,
although exogenous insulin therapy still remains a
life-saving therapy. The destructive process causing T1D
is thought to have a pertinent adaptive autoimmune
component. In fact, persuasive shreds of evidence
suggested that aberrant epigenetic modifications are in-
volved in T1D pathogenesis. The epigenetic involvement
in T1D has been nicely reviewed recently [149].
However, environmental factors, in different models of
diabetes, influence epigenetic changes and consequently
contribute significantly to altered gene expression
relevant in T1D development and progression. Over the
last decade, some studies have reported that DNA
methylation, histone modifications, and noncoding
RNAs are considered to have a crucial role in T1D.
Again, a genome-wide DNA methylation identified
SNP-CpG methylation patterns as potentially relevant
for the genetic association of insulin expression and/or
secretion in human pancreatic islets [150]. In more de-
tail, candidate genes, such as GPX7, GSTT1, and SNX19,
are known to possess a direct influence on various bio-
logical processes regarding proliferation and apoptosis in
pancreatic β cells. Another study in mouse models also
confirmed the implication of epigenetic changes in
insulin secretion and diabetes risk [151]. Patients with
T1D, compared to the healthy controls, exhibited
cell-type-specific gene regulatory circuits crucial for
immune cell metabolism and the cell cycle. The latter
includes mTOR signaling pathway implicated in the
development of diabetes-associated damage [152]. It is
believed that epigenetic alteration in diabetes might be
the cause for an increased risk for the development and
progression of vascular complications. Very likely, theseeffects are mediated through histone methyltransferases
which boost the pro-inflammatory networks implicated
in vascular injury [153–155]. Hypermethylated regions
of FOXP3 in CD4+ cells in T1D resulted in decreased
FOXP3 expression and reduced production of regulatory
T cells [156]. Additionally, Wang et al. supported the
idea of the FOXP3 involvement as its gene hypermethy-
lation was induced by Toll-like receptor 9 (TLR9) in as-
sociation with a reduced binding activity of interferon
regulator factor 7 (IRF-7) [157]. About histone modifica-
tions, increased H3K9me2 levels in the promoter of
CLTA4, a T1D susceptibility gene, has been correlated
with T cell activation [158]. Moreover, Patel et al. sug-
gested that TSA, a well-known HDACi, excites IFN-γ
production and increases the transcription activity of
Tbx21 in T lymphocytes, alleviating the inflammatory
damage of islets [159]. Since T1D shows a broad
range of miRNA expression profiles, some miRNAs
have been associated with T1D. Upregulated miR-510,
as well as the downregulation of miR-342 and
miR-191, have been described in T1D. Furthermore,
once Treg cells are compared with other types of ef-
fector T cells, data showed a substantial change in
the expression patterns of miR-146a in conjugation
with a decreased expression of eight targeting miR-
NAs (20b, 31, 99a, 100, 125b, 151, 335, and 365) thus
demonstrating the involvement of miRNAs in T1D
patients’ Treg cells [160].Benefits and risk of epigenetic therapy
As we have seen in the previous sections, mainly old
well-studied and often already approved epigenetic mod-
ulators have been used in the context of autoimmune
diseases [56, 59, 67, 81, 84, 86, 89, 103, 121, 159]. These
first-generation molecules have been originally devel-
oped as anti-tumor therapy. They often show heavy side
effects by mechanism, which are tolerable in cancer, but
not in other diseases [9, 19]. This point is one major
drawback and risk of the studies currently present in lit-
erature. The main challenge for researchers is not only
to understand better the role of epigenetics in
autoimmune disorders also with the help of epigenetic
modulators, but also to develop novel specific targeted
therapies. Interestingly, novel second or third generation
epigenetic modulators, which often have a better select-
ivity and safety profile, have been used in other medical
conditions but have not yet been applied in immuno-
therapy approaches [18, 161]. In our view, benefits
outweigh the risks as novel innovative treatments are
needed, but researchers should proceed with care
considering the selectivity and safety profile of their
potential treatments already at an early stage of the
therapy development.
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This work has been focused on epigenetic mechanisms
regulating several autoimmune disorders with the aim to
provide new therapeutic ideas in this area of interest
(Fig. 1). The link between epigenetics and autoimmunity
has been widely documented in the literature; although,
more and more extensive studies are required to better
understand the influence of these modifications in the
different autoimmune disorders. A deeper exploration of
the complex epigenetic interactions may be useful for
the development of promising treatment strategies
targeting the epigenome. The fundamental work of Farh
et al. in 2015 described a fine-mapping algorithm to
identify non-coding genetic variants that could underlie
autoimmune diseases from genotyping data [162]. How-
ever, to date, there is still a lot of research necessary in
order to provide effective healthcare solutions for such
diseases, such as an adequate choice of treatment and a
precise prediction of treatment outcomes. Epigenetics
will very likely aid to provide further progress in the field
of autoimmunity. Until now, only a few studies have
been carried out to examine the clinical applicability of
epigenetics and its modulators in such autoimmune dis-
eases. Keeping this concept in mind, more comprehen-
sive and more accessible technologies are recommended
to promote advances in the therapeutics leading to pre-
vention by early interventions and reducing both costs
and patient morbidity. Taken together, the future of epi-
genetics in autoimmunity is rapidly increasing. However,
it still needs an in-depth investigation to allow novel
potential therapeutic opportunities, better than those
currently used.
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